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Vitamin B6Primary hyperoxaluria type 1 (PH1) is a rare hereditary calcium oxalate kidney stone disease caused by a
deﬁciency of the liver-speciﬁc pyridoxal-phosphate-dependent peroxisomal enzyme alanine:glyoxylate
aminotransferase (AGT). About one third of patients are responsive to pharmacological doses of pyridoxine
(vitamin B6), but its mechanism of action is unknown. Using stably transformed Chinese Hamster Ovary
(CHO) cells expressing various normal and mutant forms of AGT, we have shown that pyridoxine increases
the net expression, catalytic activity and peroxisomal import of the most common mistargeted mutant
form of AGT (i.e. Gly170Arg on the background of the polymorphic minor allele). These multiple effects ex-
plain for the ﬁrst time the action of pyridoxine in the most common group of responsive patients. Partial ef-
fects of pyridoxine were also observed for two other common AGTmutants on the minor allele (i.e. Phe152Ile
and Ile244Thr) but not for the minor allele mutant AGT containing a Gly41Arg replacement. These ﬁndings
demonstrate that pyridoxine, which is metabolised to pyridoxal phosphate, the essential cofactor of AGT,
achieves its effects both as a prosthetic group (increasing enzyme catalytic activity) and a chemical chaper-
one (increasing peroxisome targeting and net expression). This new understanding should aid the develop-
ment of pharmacological treatments that attempt to enhance efﬁcacy of pyridoxine in PH1, as well as
encouraging a re-evaluation of the extent of pyridoxine responsiveness in PH1, as more patients than previ-
ously thought might beneﬁt from such treatment.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Primary hyperoxaluria type 1 (PH1, OMIM 259900) is a rare hered-
itary disorder characterised by the chronic over-production of the met-
abolic end-product oxalate and the progressive deposition of insoluble
calcium oxalate in the kidney and urinary tract as urolithiasis and
nephrocalcinosis. The ensuing chronic kidney failure leads to the depo-
sition of calcium oxalate throughout the body (systemic oxalosis). PH1
is caused by a deﬁciency of the enzyme alanine:glyoxylate aminotrans-
ferase (AGT, EC 2.6.1.44) [1]. AGT is a pyridoxal-phosphate (PLP)-
dependent liver-speciﬁc peroxisomal enzyme which catalyses the
transamination of the intermediary metabolite glyoxylate to glycine.
In PH1, AGT deﬁciency allows the glyoxylate to diffuse through the per-
oxisomal membrane into the cytosol where it is oxidised to oxalate
catalysed by lactate dehydrogenase.rase; FBS, fetal bovine serum;
ng sequence; PH1, primary
lopmental Biology, Division of
ndonWC1E 6BT, UK. Tel.: +44
l rights reserved.It has been known for many years that pyridoxine, a metabolic pre-
cursor of the cofactor PLP, can reduce oxalate excretion in about one
third of PH1 patients [2–5], but the mechanisms by which this occurs
have never been elucidated. Recently it has been shown that pyridoxine
responsiveness is associated with two particular missense mutations in
the AGT gene (AGXT) which lead to Gly170Arg and Phe152Ile amino
acid replacements [6–8]. These two mutations have a combined allelic
frequency of 30–40% in PH1 patients [6,9–11] and both segregate with
the “minor” AGXT allele [6,12,13]. The latter differs from themore com-
mon “major” allele most importantly by a single base change, which
leads to a Pro11Leu amino acid replacement in the AGT protein [13].
In patients expressing Gly170Arg-mutant AGT, the disease is due to an
unparalleled protein trafﬁcking defect in which the normally peroxi-
somal AGT is mistargeted to the mitochondria [13,14]. Although
mistargeted AGT retains some catalytic activity, it is metabolically inef-
fective. The mistargeting results from the synergistic interaction of the
Pro11Leu-generated cryptic mitochondrial targeting sequence (MTS)
and the Gly170Arg mutation, which together delay folding and
dimerisation or otherwise destabilise the protein, resulting in exposure
of the cryptic MTS and mitochondrial import. Recently, it has been
shown that three other mutations (i.e. Phe152Ile, Ile244Thr, Gly41Arg),
which segregate with the minor allele, are also at least partially
mistargeted [15]. However, whether pyridoxine responsiveness is
Fig. 1. Levels of B6 vitamers in transformed CHO cells. The B6 vitamer content of cell
lysates (nmol/g cell protein) was analysed by HPLC followed by tandem mass-
spectrometry. The CHO cells were grown at least 4 weeks with different levels of
pyridoxine—1: 0 μM, 2: b0.3 μM, 3: 0.3 μM, 4: 50 μM, 5: 250 μM. PL: pyridoxal; PLP: pyr-
idoxal 5′-phosphate; PA: pyridoxic acid; PN: pyridoxine; PNP: pyridoxine phosphate;
PMP: pyridoxamine 5′-phosphate; PM: pyridoxamine. The results shown are the average
and range of 3 different CHO cell lines, expressing GO only, GO and AGT-MA, and GO and
AGT-170. A. The tandemmass-spectrometrywas kindly performedbyEmma Footitt at the
Institute of Child Health (Clinical andMolecular Genetics Unit, University College London,
London, UK) [20].
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is unknown.
In the present study, we have investigated the mechanisms by
which pyridoxine achieves its effects in responsive PH1 patients in a
specially developed system of transformed CHO cells stably express-
ing various normal and mutant AGTs. We show that pyridoxine has
multiple effects on the Gly170Arg mutant, including increasing its
net expression, catalytic activity, and peroxisomal targeting. Some
of these effects are also found with other mutant AGTs, suggesting
that pyridoxine responsiveness might be more widely spread across
the cohort of PH1 patients than previously thought.
2. Materials and methods
2.1. Expression constructs
The full-length normal human AGT cDNAs (AGT-MA and AGT-mi),
the mutant human AGT cDNAs (AGT-170, AGT-152, AGT-244 and
AGT-41), and the normal human glycolate oxidase (GO) cDNA were
generated as described previously [15–19] and subcloned in the
mammalian expression vectors pcDNA3.1(+)neo and pcDNA3.1(−)
zeo, respectively (both Invitrogen, Carlsbad, CA). The properties of
the encoded AGT enzymes in various systems are listed in Table 1.
2.2. Cell lines, transformation and culture
CHO cells were initially transformed with full-length GO cDNA
and then retransformed with various full-length normal or mutant
AGT cDNAs, as described before [15,19]. Seven different transformed
CHO cell lines were used in the present study: two expressed the nor-
mal AGT polymorphic variants (AGT-MA and AGT-mi) and four
expressed the PH1 mutant AGTs (AGT-170, AGT-152, AGT-244,
AGT-41). All of the cell lines expressing the AGT variants also
expressed GO. In addition, one cell line expressed GO only and an
untransformed cell line expressed neither AGT nor GO (i.e. wild-
type CHO cells). Transformed and wild-type CHO cells were cultured
in Ham's F12 medium supplemented by 10% fetal calf serum, as de-
scribed before [15,19]. Expression of AGT and GO was maintained
by adding Geneticin (800 μg/ml) and Zeocin (400 μg/ml), respective-
ly, to the culture medium. The levels of expression of AGT and GO in
the transformed cell lines remained stable over a period of at least
3 months. All cell culture reagents were from Invitrogen (Carlsbad,
CA).
2.3. Pyridoxine and B6 vitamers
Varying the pyridoxine concentration in the cells was achieved by
growing cells for a minimum of four weeks in medium containing
different pyridoxine concentrations. The standard pyridoxine concen-
tration (0.3 μM) was obtained by culture in Ham's F12 and normal
FBS. For higher pyridoxine concentrations, pyridoxine hydrochloride
(Sigma, St. Louis, Missouri) was added to the culture to ﬁnalTable 1
Properties of normal and mutant forms of AGT used in the present study.
AGT construct Amino acid changes
compared to AGT-MA
Enzyme activity in human
liver compared to AGT-MA (%)
Intrac
Stably
AGT-MA1 [100] P
AGT-mi2 P11L, I340M 90 P + m
AGT-413 P11L, G41R, I340M 0 M +
AGT-1523 P11L, F152I, I340M 0–16 M +
AGT-1703 P11L, G170R, I340M 10–72 M +
AGT-2443 P11L, I244T, I340M 0–36 M +
1: normal AGT encoded by themajor AGXT allele; 2: normal AGT encoded by theminor AGXT all
cores as extrapolated from a compound AGT-41/AGT-152 compound heterozygote; 5: distri
major/minor mitochondrial localisation; P/p: major/minor peroxisomal localisation. Uox: urinconcentrations of 50 μM and 250 μM. For lower pyridoxine concentra-
tions, a specialty Ham's F12 medium without B6 vitamers was used
either supplemented with normal FBS or dialysed FBS (cut-off
10,000 MW). The concentrations of B6 vitamers in cells cultured in
the ﬁve different pyridoxine concentrations was measured by HPLC-
Tandem Mass Spectrometry, kindly performed by Emma Footitt at the
Clinical and Molecular Genetics Unit (Institute of Child Health, Univer-
sity College London, UK) [20]. Based on the measured residual intracel-
lular levels of B6 vitamers and holo-AGT-MA (see Figs. 1 and 4), only
60% of the pyridoxine and other B6 vitamers were removed from the
system with the use of “pyridoxine-free” Ham's F12 medium and nor-
mal FBS (referred to as “b0.3 μM”), compared with 85% when
“pyridoxine-free” and dialysed FBS were used (referred to as “zero”).
The exact concentrations of B6 vitamers in the culture medium could
not be determined at these two lower concentrations and the origin of
the 15% residual levels remaining is at present unclear.
2.4. Immunoﬂuorescence microscopy and image analysis
Cells on 13 mm glass coverslips were prepared for immunoﬂuores-
cence (IMF) microscopy and stained as previously described with vari-
ous combinations of MitoTracker (Red, CMXRos, Invitrogen, Carlsbad,
CA), rabbit or guinea-pig polyclonal anti-human AGT and anti-human
GO primary antibodies followed by incubation with Alexa-conjugated
secondary antibodies (AlexaFluor 488 and 568, Invitrogen, Carlsbad,
CA) and nuclei staining with Hoechst 33258. The coverslips were
mounted over slides in Citiﬂuor mounting medium (Citiﬂuor) [19,21].ellular localisation Effects of B6 vitamers
transformed CHO cells Liver
P PLP stabilises pure protein
P + m PLP stabilises pure protein
P p4 PLP stabilises pure protein
p m + p5 Pyridoxine reduces Uox in PH1 patients
p M + p Pyridoxine reduces Uox in PH1 patients
P unknown unknown
ele; 3:mutant AGTs found in PH1 all on the background of theminor allele; 4: peroxisomal
bution extrapolated from a compound AGT-41/AGT-152 compound heterozygote. M/m:
ary oxalate. Information taken from multiple source.[6,7,9,11,12,15,17,34,38,47–50].
Fig. 2. Effect of pyridoxine on the net expression of AGT-MA, AGT-mi and AGT-170 in
stably transformed CHO cells. CHO cells stably expressing AGT-MA or AGT-170 or
AGT-mi were grown at least 4 weeks in various concentrations of pyridoxine—1:
0 μM, 2: b0.3 μM, 3: 0.3 μM, 4: 50 μM, 5: 250 μM. Five micrograms of cell protein
lysates were loaded on each lane of a SDS-PAGE gel and blotted against guinea-pig
anti human AGT (upper box). AGT monomer runs at ~43 kDa, whereas the dimeric
isoforms run at 80–90 kDa. Control loading of lanes is shown by subsequent GAPDH
staining in the lower box.
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laser-scanning ﬂuorescence microscope (Leica TCS SPE, Leica Micro-
systems, Wetzlar, Germany) with a 40× or 63× oil immersion lens
(apochromat, NA: 1.33) and the focal z-step kept between 200 and
300 nm. If necessary registration correction was performed on images
using the TransformJ/Translate plugin in ImageJ developed by
E. Meijering with predetermined parameters. The image analysis was
carried out using ImageJ software (Rasband, W.S., ImageJ, U.S. National
Institutes of Health, Bethesda,Maryland, USA, http://rsb.info.nih.gov/ij/,
1997–2008). For quantitative colocalisation analysis, Manders and
Pearson coefﬁcients were calculated on whole image stacks for 10–20
cells selected randomly using the ImageJ JACoP plugin [22] with manu-
ally set thresholds.
2.5. Immunoblotting
Cell lysates were analysed by SDS-PAGE and immunoblotting as
previously described [15,19]. Brieﬂy, cells were resuspended in lysis
buffer (1% v/v Triton X100, 3mM EDTA, protease inhibitor cocktail
(Roche)), snap-frozen on dry ice before thawing out at 37°, followed
by 4 cycles of sonication (Bioruptor, Diagenode). Protein concentra-
tion was determined on sonicates using the Bradford Reagent kit
(Sigma-Aldrich). Aliquots of 5 μg of cell protein were loaded into
each lane of a precast Bis–Tris 10% NuPAGE gel (Invitrogen Ltd,).
After transfer onto a Westran PVDF membrane (Whatman), the
membranes were blocked in 5% non-fat dry milk in TBS-T (154 mM
NaCl, 15 mM Tris–HCl, pH 7.5, 0.5% Tween 20) and incubated with
primary antibodies (polyclonal guinea-pig anti human AGT [15,19]
or mouse anti-human GAPDH (Santa Cruz)) followed by the appro-
priate secondary antibodies conjugated to peroxidase. The signal
was detected using an EZ-ECL chemiluminescence kit (Biological In-
dustries). For densitometry analysis of western blots, the chemilumi-
nescent signal was recorded from the membrane with a Camera
(ImageQuant LAS 4000, GE Healthcare, Little Chalfont, England) and
analysed using the measure tool in ImageJ. Results were expressed
relative to the densitometry of AGT-MA in each gel analysed. Control
of the loading of each lane was done by a GAPDH staining following
the AGT staining on the membranes.
2.6. Catalytic activity
AGT activities in cell lysates weremeasured as published previously
by a spectrophotometric method, either with or without 150 μMPLP in
the assay [15,19,23].
3. Results
3.1. Intracellular concentrations of B6 vitamers are markedly inﬂuenced
by extracellular pyridoxine concentrations
In order to study the effects of extracellular pyridoxine on the intra-
cellular levels of B6 vitamers, CHO cells stably expressing various nor-
mal and mutant AGT constructs were cultured in medium containing
different concentrations of pyridoxine hydrochloride for a minimum
of four weeks. Although the intracellular concentrations of pyridoxic
acid and pyridoxamine remained below the levels of detection, the
intracellular concentrations of all the other metabolites were strongly
dependent on the extracellular pyridoxine concentration (Fig. 1). The
AGT cofactors, PLP and pyridoxamine-5′-phosphate, both increased as
the extracellular concentration of pyridoxine increased from zero to
0.3 μM. Further increases in pyridoxine in the culture medium up to
250 μM, failed to elicit any further increase in intracellular PLP or
pyridoxamine-5′-phosphate levels. The intracellular levels of pyridox-
ine phosphate and unmetabolised pyridoxine were below the levels of
detection at extracellular pyridoxine concentrations ≤0.3 μM, but
markedly increased at higher concentrations (50/250 μM).3.2. The net expression of mutant AGTs, but not normal AGTs, is a function
of extracellular pyridoxine concentration
The net expression (i.e. the difference between synthesis and deg-
radation) of immunoreactive AGT in cells expressing various normal
and mutant AGT constructs was studied by SDS-PAGE and immuno-
blotting. The immunoblot for AGT-170 are shown in Fig. 2 and the
densitometric analysis for all AGT variants in Fig. 3. Although the ex-
pression of the normal AGT constructs (i.e. AGT-MA and AGT-mi)
remained unaltered as the extracellular levels of pyridoxine were
increased, the net expression of the mutants all increased. As the pyr-
idoxine concentration increased from zero to 0.3 μM, the net expres-
sion of AGT-170 increased by a factor of 2–3. Further increases in
pyridoxine concentration up to 250 μM increased expression only
marginally. The increased expression of the other mutants was less
clear-cut, partly due to the wide range of the densitometric values. Al-
though the cell lysates were electrophoresed under denaturing condi-
tions, under which AGT should run at its monomeric size of 43 kDa, it
has been reported before [15] that some of the very stable AGT dimers
can, under certain circumstances, still run as 80–90 kDa multiple
dimer bands. These detergent-resistant dimers were much more
prominent for AGT-mi and the mutants than for AGT-MA (Figs. 2–3)
and more prominent at the lower pyridoxine concentrations.
3.3. The intracellular levels of both apo-AGT and holo-AGT are markedly
inﬂuenced by extracellular pyridoxine concentrations
The catalytic activity of AGT variants in cells exposed to different
pyridoxine concentrations was assayed in the absence of PLP to deter-
mine the levels of holo-enzyme in the cell lysates and in the presence
of 150 μM PLP to determine the maximal recoverable activity of AGT.
The difference between the two measurements represents the amount
of apo-AGT in the cell lysates. As expected, the catalytic activity of AGT
in stably transformed CHO cells was very dependent on the extracellu-
lar concentrations of pyridoxine and hence the intracellular concentra-
tions of its cofactor PLP (Fig. 4). The activities of the normal constructs
(i.e. AGT-MA and AGT-mi) in the absence of added PLP (holo-enzyme
levels) increased as the pyridoxine concentration was increased from
zero to 0.3 μM. Surprisingly, further increases in pyridoxine concentra-
tion to 50 μM and 250 μM led to a marked decrease in activity. Despite
the low AGT activities in the assay without PLP for cells grown at low
pyridoxine concentrations, the addition of PLP to the assay brought
about a complete recovery, in the case of AGT-MA, and partial recovery,
Fig. 3. Estimation of the average effect of pyridoxine on the net expression of AGT in
CHO stable transformants as assessed by densitometry. CHO cells stably expressing
the different AGT variants (AGT-MA, AGT-mi, AGT-170, AGT-152, AGT-244, AGT-41)
were grown at least 4 weeks in various concentrations of pyridoxine—1: 0 μM, 2:
b0.3 μM, 3: 0.3 μM, 4: 50 μM, 5: 250 μM. The band intensities were quantiﬁed from
western blots of whole cell lysates. (A): intensity of AGT monomer band; (B): intensity
of AGT dimer or multimer (for AGT-41) bands; (C): intensity of all total AGT bands
together. The results are normalised to the intensities of the total of all the bands
together for the 0.3 μM pyridoxine concentration for each AGT construct and averaged
(+SD; n = 2–8). The statistical signiﬁcance of a change in expression of AGT variants
was calculated with Student t-test and is marked, when signiﬁcant, with asterisks:
(*) p b 0.05, (**) p b 0.001.
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0.3 μM pyridoxine. At the very high pyridoxine concentrations the ac-
tivities of AGT-MA and AGT-mi remained low even with added PLP in
the assay. The mutant AGT constructs behaved rather differently to
the normal AGT constructs. The catalytic activities assayed without
PLP of AGT-170 and AGT-244 increased as pyridoxine concentrations
in the culture medium increased up to 0.3 μM and did not increase fur-
ther for higher pyridoxine concentrations. Little or no activity at low
pyridoxine concentrations could be recovered by adding PLP to the
assay. For AGT-152, the activities remained low in the absence of PLP
in the assay, but increased as pyridoxine concentrations increasedfrom 0.3 μM to 50 μMwhen assayed in the presence of PLP. Extracellu-
lar pyridoxine had very little effect on the very low activities of AGT-41,
with or without PLP in the assay.
3.4. The targeting of some, but not all, mutant AGTs to peroxisomes
increased with increasing extracellular pyridoxine concentrations
We investigated the effects of extracellular pyridoxine on the intra-
cellular compartmentalisation of various mutant AGT constructs, all
known to be mistargeted [15], using immunoﬂuorescence microscopy.
Analysis of the resultswas carried out both qualitatively (Fig. 5 and Sup-
plementary Figs. 1–4) and quantitatively using Pearson and Manders
coefﬁcients (Fig. 6). As expected, the distribution of normal AGT-MA
(Supplementary Fig. S1) was entirely peroxisomal (i.e. co-localised
with the peroxisomalmarker glycolate oxidase, GO) andwas unaffected
by pyridoxine concentration. On the other hand, AGT-170 (Fig. 5) and
AGT-152 (Supplementary Fig. S2) were almost entirely excluded from
peroxisomes (i.e. not co-localised with GO) at low pyridoxine concen-
trations. The immunoﬂuorescence images show a classical mitochon-
drial distribution of these AGT mutants, as we have shown previously
[15]. As the pyridoxine concentration increased to 0.3 μM, the
localisation to peroxisomes increased, although most still remained in
themitochondria. The distribution did not further change at 50 μMpyr-
idoxine concentration. The effects of pyridoxine on AGT-244 distribu-
tion were more equivocal. The correlation coefﬁcients suggested a
minor shift of distribution towards the peroxisomes, without reaching
statistical signiﬁcance (Fig. 6A–B). Pyridoxine had no obvious effect on
the distribution of AGT-41.
4. Discussion
In addition to PH1, pyridoxine has been used to treat a variety of
inborn errors of metabolism caused by dysfunction of PLP-dependent
enzymes, such as ornithine δ-aminotransferase, tyrosine aminotrans-
ferase and δ-aminolevulinate synthase [24–27]. Pyridoxine has been
shown to increase the stability or activity of these enzymes in puriﬁed
protein systems [28,29] and in cell and animal models [24,25,29–33].
As far as PH1 is concerned, a number of studies have shown that PLP
stabilises puriﬁed recombinant AGT to different extents [34–38]. How-
ever, the mechanism of action of pyridoxine at a cellular level has
remained elusive. In an attempt rectify this situation, we have devel-
oped a simple and tractable system based on the steady-state expres-
sion of normal and mutant forms of AGT in transformed CHO cells and
investigated the effects of altering the extracellular pyridoxine concen-
tration on various properties of AGT, including net expression, catalytic
activity, and peroxisomal localisation.
The concentration of pyridoxine in Ham's F12, the normal medium
for CHO cells, is ~0.3 μM, which is similar to the plasma level of B6
vitamers found in pyridoxine-treated patients [20,39–44]. In thepresent
study, as extracellular pyridoxine levels increased from nominally zero
to 0.3 μM, the intracellular levels of PLP rose from 20 to 100 nmol/g
cell protein. There was no further increase in intracellular PLP levels
for higher extracellular pyridoxine concentrations, suggesting that the
normal intracellular concentration of PLP in the CHO cells is somewhat
(possibly signiﬁcantly) below 100 nmol/g cell protein, which corre-
sponds to an extracellular pyridoxine concentration in the medium
probably well below 0.3 μM.
It is clear from the present study that pyridoxine has multiple ef-
fects on AGT. These effects, the relative importance of which varies
between the different AGT constructs, are indirect in so far as they
are likely to result from its effect on intracellular concentrations of
PLP (and possibly pyridoxamine-5′-phosphate). Intracellular PLP
appears to work, not only as a simple prosthetic group (increasing
catalytic activity), but also as a chemical chaperone (increasing net
expression and peroxisomal import).
Fig. 4. Effect of pyridoxine on the catalytic activity of AGT in transformed CHO cell lines. The catalytic activity of AGT in the presence (150 μmol/l) or absence of added PLP in the
assay was measured on cell lysates obtained from cells grown at least 4 weeks in the various pyridoxine concentrations—1: 0 μM, 2: b0.3 μM, 3: 0.3 μM, 4: 50 μM, 5: 250 μM. Cells
expressed various AGT constructs—AGT-MA, AGT-mi, AGT-170, AGT-152, AGT-244, AGT-41-; GO: cells expressing GO only; WT: wild-type untransformed CHO cells. AGT activity
(μmol pyruvate/h/mg cell protein) was measured in the absence (grey histograms) or in the presence of 150 μM PLP (white histograms). The results are given as means of several
assays (+SD; n = 2–8). The limit of sensitivity of the AGT assay is 3 μmol pyruvate/h/mg of cell protein. The statistical signiﬁcance of the differences in AGT activity in the absence
of PLP for each pyridoxine concentration was compared with that at 0.3 μM pyridoxine, using Student t-test, and is shown thus: (*) p b 0.05; (**) p b 0.01; (***) p b 0.001. The
statistical signiﬁcance of the differences between AGT activity in the presence versus absence of PLP for each pyridoxine concentration, using Student t-test, and is shown thus:
(§): p b 0.05; (§§) p b 0.01; (§§§) p b 0.001. All other differences were non-signiﬁcant.
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um did not signiﬁcantly change the net expression or intracellular
localisation of normal immunoreactive AGT (i.e. AGT-MA and AGT-mi)
but, as expected, had a marked effect on their holo-enzyme levels. The
low enzyme activities of AGT-MA at low pyridoxine concentrations
could be increased to maximal levels by the addition of PLP to the
assay. On the other hand, although the low activity of AGT-mi at low
pyridoxine concentrations could also be increased by added PLP, they
remained below that found for 0.3 μM extracellular pyridoxine. These
results indicate that the total level of AGT-MA (holo-AGT-MA plus
apo-AGT-MA) is not affected by the extracellular pyridoxine concentra-
tion or presumably the intracellular PLP level. On the other hand, the
total level of holo-AGT-mi and recoverable apo-AGT-miwas signiﬁcant-
ly reduced at zero pyridoxine concentrations compared with the maxi-
mum value at 0.3 μM pyridoxine. This is particularly interesting as the
net expression of immunoreactive AGT-mi, like that of AGT-MA, was
not affected by pyridoxine concentration. The most likely explanation
of these results is that whereas all the inactive AGT-MA at low pyridox-
ine concentrations is recoverable, and therefore folded and dimerised
properly, a signiﬁcant proportion of the inactive AGT-mi at lowpyridox-
ine concentrations has misfolded/misdimerised and therefore cannot
regain catalytic activity even with the addition of PLP to the assay.
Taken together, these data show that AGT-MA and AGT-mi behave sig-
niﬁcantly differently to changes in extracellular pyridoxine concentra-
tion from zero to the normal Ham's F12 concentration of 0.3 μM. The
effects on AGT-MA can be explained entirely by the prosthetic group ef-
fect of PLP. On the other hand, the effects on AGT-mi seem to be partly
due to its prosthetic group effect and partly due to its effect as a chem-
ical chaperone, which aids the enzyme's proper folding and/or
dimerisation, and thereby acquisition of functional (i.e. catalytic) activ-
ity. Interestingly, further increases in pyridoxine levels (above 0.3 μM)had a negative effect on the activity of both AGT-MA and AGT-mi. The
reason for this is unclear but might be associated with the appearance
of abnormal intracellular B6 metabolites such as pyridoxine phosphate
and unmetabolised pyridoxine. Although undetectable or present at
very low levels in normal plasma, these B6 vitamers have been reported
in the plasma of some patients treated with high doses of pyridoxine
[40–43].
Although no inhibition of the mutant forms of AGT could be seen
at the highest pyridoxine concentrations in this study, it is possible
that excessive doses of pyridoxine in PH1 patients could result in an
increase in urinary oxalate following the initial decrease at lower
doses. In the absence of data originating from patients, and since
most patients respond at lower doses of pyridoxine (b10 mg/kg per
day [8]), these results would suggest that the dose of pyridoxine ad-
ministered to PH1 patients should be adjusted to ﬁt the best clinical
response after monitoring urinary oxalate.
All the AGTmutants studied behaved very differently to either of the
normal forms of AGT. For the AGT-170 mutant, increasing the pyridox-
ine concentration in the culture medium up to 0.3 μM was associated
with a signiﬁcant increase in net expression level and catalytic activity
in the absence of added PLP (i.e. holo-enzyme), though remaining
below the levels found for normal AGTs. No further increases were
seen for higher pyridoxine concentrations (50 μM & 250 μM) and no
enhancement of activity when PLP was added to the assay for any of
the pyridoxine concentrations. This indicates that all of the, albeit
lower, enzyme that was present was already in holo form and none in
a recoverable apo form. The most likely interpretation of this is that
AGT-170 is unstable and readily degraded in the absence, or presence
of low levels, of pyridoxine. The intracellular compartmentalisation of
AGT-170 was also signiﬁcantly altered by increasing pyridoxine
concentrations, so that more AGT was targeted to its correct location
Fig. 5. Effect of pyridoxine on the subcellular distribution of AGT-170 as shown by immunoﬂuorescence microscopy. Cells expressing AGT-170 and GO were grown at least 4 weeks
in the various concentrations of pyridoxine—1: 0 μM, 2: b0.3 μM, 3: 0.3 μM, 4: 50 μM—and stained with anti AGT (pseudo-coloured in green), anti GO (pseudo-coloured in magen-
ta), Hoechst (blue). (A): merged and single channel images from a single z-plane are shown for each pyridoxine level; (B): z-axis reslice and (C): RGB (red–green–blue) proﬁle
plotted, both along the line drawn in (A). Scale bar: 10 μm. In (A), the overlay of magenta in green, indicating colocalization between AGT and GO, results in a white colour. In
each panel, a white arrow points to a peroxisome for easier alignment of the images.
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still remained mitochondrial and, although the increased proportion of
AGT-170 imported into peroxisomes could not be determined, the per-
oxisomal shift was clear on immunoﬂuorescence microscopy (Fig. 5).
The outcome of this is that the amount of intraperoxisomal catalytically
active AGT-170 increasedmarkedly, as pyridoxine levels increased from
zero to 0.3 μM concentration and probably plateaued thereafter.
Increased net expression and peroxisomal localisation of AGT-170, as
pyridoxine concentrations increase, are compatible with increased pro-
ductive folding/dimerisation and improved protein stability [15]. Thus
in the case of AGT-170, extracellular pyridoxine, via intracellular PLP,
appears to exert its effect mainly as a chemical chaperone rather than
a prosthetic group.
These ﬁndings provide for the ﬁrst time a rational explanation as
to how pyridoxine achieves its therapeutic effects in the largest
group of pyridoxine-responsive PH1 patients. Although extrapolationof the results of our cell-based system to actual PH1 patients must re-
main somewhat speculative, the reduction of urinary oxalate seen in
responsive patients bearing the Gly170Arg mutation could be due to
the signiﬁcant increase (possibly doubling) of catalytically active per-
oxisomal (i.e. metabolically effective) AGT, as seen in the present
study as the pyridoxine concentration is increased from b0.3 to
0.3 μmol. This could elevate the metabolic effectiveness of AGT to
levels found in asymptomatic carriers.
Over amore limited range of pyridoxine concentrations, AGT-152, the
other mutant form of AGT associated with pyridoxine responsiveness in
PH1 patients, behaved similarly to AGT-170 in terms of net expression
and intracellular localisation, but rather differently in terms of catalytic
activity. Its activity in the absence of added PLP (i.e. holo-enzyme) was
very low at all pyridoxine concentrations, but the amount of apo-
protein increased noticeably when pyridoxine concentration increased.
Previous work on puriﬁed recombinant AGT had suggested a prosthetic
Fig. 6. Quantitative analysis of the effect of pyridoxine on the subcellular distribution of
AGT variants based on immunoﬂuorescence microscopy. Pearson and Manders
colocalization coefﬁcients were calculated on immunoﬂuorescence images from cells
expressing AGT grown at least 4 weeks in various concentrations of pyridoxine—1:
0 μM, 2: b0.3 μM, 3: 0.3 μM, 4: 50 μM. (A): Pearson colocalization coefﬁcient, calculat-
ed for the colocalization of AGT and GO (i.e. peroxisomes); (B): Manders M1 coefﬁ-
cients for the colocalization of AGT with the peroxisomal marker GO; (C): Manders
M2 coefﬁcients for the colocalization peroxisomal marker GO with AGT. Coefﬁcients
were calculated using the ImageJ JACoP plugin, with manual thresholding, on image
stacks of cells stained with anti-AGT and anti-GO. The results are given as means
(+SD) of several images; stack images of at least 10 individual cells were analysed
for each coefﬁcient. The statistical signiﬁcance of the change in AGT localization com-
pared to 0.3 μM pyridoxine was calculated with Student t-test and is marked, when
signiﬁcant, with asterisks; (*): p b 0.05; (**): p b 0.01; (***): p b 0.001.
1782 S. Fargue et al. / Biochimica et Biophysica Acta 1832 (2013) 1776–1783group effect of PLP on AGT-152 [38]. The present results suggest that the
effect of pyridoxine (via PLP) can be mainly explained by a prosthetic
group, and possibly a minor chemical chaperone, effect. Again, AGT-244
was partly similar to AGT-170 insofar as net expression and catalytic
activity increased with increasing pyridoxine concentrations, although
peroxisomal localisation did not change signiﬁcantly. The clinical
pyridoxine-responsiveness of the AGT-244 mutation is not well studied,
but a recent publication reported responsiveness in a PH1 patient homo-
zygous for the Ile244Thr mutation [45]. AGT-41, for which there is no
report of pyridoxine responsiveness in patients, was different to all the
other mutants in the present study as pyridoxine had little or no effect
on any of the parameters measured.The CHO cell-based study described in this paper has the great
advantage in that it allows investigation of the proximal effects of
pyridoxine (via pyridoxal phosphate) within the cell, albeit not a
liver cell. It allows individual mutations to be studied without the in-
terference of background AGT found in transformed liver cell lines, for
example. Such a system allows us to ﬁll the gap between studies on
the effects of pyridoxal phosphate on puriﬁed recombinant AGT pro-
tein, on the one hand, and the effects of pyridoxine on urinary oxalate
excretion in patients, on the other. The results of the present study
can probably be safely extrapolated at the qualitative level to PH1
patients. However, they cannot be done so with any certainty at
the quantitative level, nor does it allow quantitative comparisons
between AGT variants in the cells. Although the present study
concerned only mutations found on the background of the minor
allele, there is every reason to suppose that it would be equally infor-
mative for mutations expressed on the background of the major
allele, although organelle targeting would not be an issue with the
latter mutants.
4.1. Conclusion
In conclusion, the present studies provide for the ﬁrst time a rational
explanation for the therapeutic effect of pyridoxine treatment in PH1
patients, with both chemical chaperone and prosthetic group effects,
depending on the mutant. They also suggest that more patients than
previously thoughtmight respond to pharmacological doses of pyridox-
ine, and reinforce the current recommendations to test the pyridoxine-
responsiveness in all PH1patients. In addition to its role as a therapeutic
agent, pyridoxine might also be expected to act synergistically with
other pharmacological treatments of PH1 in combined therapies, as
has been suggested for Fabry disease [46].
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